FCMI
DNLI icon

Foresite Capital Management II’s Denali Therapeutics DNLI Stock Holding History

Foresite Capital Management II’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-250,000
Closed -$5.43M – 11
2018
Q3 		$5.43M Hold
250,000
– – 2.01% 8
2018
Q2 		$3.81M Hold
250,000
– – 1.34% 8
2018
Q1 		$3.7M Hold
250,000
– – 1.23% 9
2017
Q4 		$3.91M Buy
+250,000
New +$4.49M 1.37% 7

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Foresite Capital Management II's DNLI Position: Q4 2018 in Review

Foresite Capital Management II sold out of Denali Therapeutics (DNLI) in Q4 2018, closing a stake of 250,000 shares — an estimated $5.43M sold.

Foresite Capital Management II first reported a position in DNLI in Q4 2017 and held it in 4 quarters. The position peaked at $5.43M in Q3 2018. 90 funds tracked by Wall St. Rank hold DNLI as of Q4 2018.

  • Foresite Capital Management II reported no remaining Denali Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Foresite Capital Management II sold 250,000 Denali Therapeutics shares in Q4 2018, an estimated $5.43M.
  • Foresite Capital Management II first reported a position in Denali Therapeutics in Q4 2017 and held it in 4 quarters.
  • Foresite Capital Management II's Denali Therapeutics position peaked at $5.43M in Q3 2018.
  • 90 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2018.

Based on Foresite Capital Management II's 13F filing for Q4 2018, filed 13 Feb 2019.